VivoSeq
Oncology

Extrapulmonary Neuroendocrine Cancer

3

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Extrapulmonary Neuroendocrine Cancer is an early-stage landscape with 3 programs across 2 companies. The most active players are Avyxa, Boehringer Ingelheim. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

2 programs

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 33

Obrixtamig

Boehringer Ingelheim

Carboplatin

Avyxa

Etoposide

Avyxa

Approved
No programs

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas
Not yet recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT07544654·390 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)